Novo Nordisk, Ypsomed and CagriSema
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China ...
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday ...
About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback